GlaxoSmithKline (GSK.US) plans to invest up to $2 billion in acquiring a liver disease drug.

According to the WiseFinance APP, GlaxoSmithKline (GSK.US) will acquire the main assets of Boston Pharmaceuticals, an experimental drug called efimosfermin alfa for treating liver diseases, for up to $2 billion in cash. GlaxoSmithKline stated on Wednesday that the treatment developed by Boston Pharmaceuticals is ready to enter the final stage of clinical trials and has the potential to become a leading drug for treating a type of fatty liver disease.